A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

Shapira-Frommer, R; Oza, AM; Domchek, SM; Balmana, J; Patel, MR; Chen, LM; Drew, Y; Burris, HA; Korach, J; Flynn, M; Bowering, VL; Morgan, MA; Watkins, SP; Simpson, D; Goble, S; Maloney, L; Kristeleit, RS

A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

Lookup NU author(s): Dr Yvette Drew ORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Shapira-Frommer R, Oza AM, Domchek SM, Balmana J, Patel MR, Chen LM, Drew Y, Burris HA, Korach J, Flynn M, Bowering VL, Morgan MA, Watkins SP, Simpson D, Goble S, Maloney L, Kristeleit RS

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 2015 ASCO Annual Meeting

Year of Conference: 2015

Print publication date: 20/05/2015

Acceptance date: 01/01/1900

ISSN: 0732-183X

Publisher: American Society of Clinical Oncology

URL: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/5513?sid=ce0cb2c2-4cc1-4296-a1a9-377b13355fe7

Series Title: Journal of Clinical Oncology

ePrints

A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

Downloads

Publication metadata

Share